StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.12−0.11 (-0.52%)

Close on Nov 17, 2026Market cap $6.74BP/E 43.1Yield –

Amneal Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Amneal Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $3.12B, up 9.3% year over year. For fiscal 2025 it was $3.02B, up 8.0% from the year before. The highest annual figure on record is $3.02B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.02B+8.0%
FY2024Dec 31, 2024$2.79B+16.7%
FY2023Dec 31, 2023$2.39B+8.2%
FY2022Dec 31, 2022$2.21B+5.7%
FY2021Dec 31, 2021$2.09B+5.1%
FY2020Dec 31, 2020$1.99B+22.5%
FY2019Dec 31, 2019$1.63B-2.2%
FY2018Dec 31, 2018$1.66B+60.9%
FY2017Dec 31, 2017$1.03B+1.5%
FY2016Dec 31, 2016$1.02B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$796.20M+9.9%
Q1 FY2026Mar 31, 2026$722.52M+3.9%
Q4 FY2025Dec 31, 2025$814.32M+11.5%
Q3 FY2025Sep 30, 2025$784.51M+11.7%
Q2 FY2025Jun 30, 2025$724.51M+3.2%
Q1 FY2025Mar 31, 2025$695.42M+5.5%
Q4 FY2024Dec 31, 2024$730.52M+18.4%
Q3 FY2024Sep 30, 2024$702.47M+13.3%
Q2 FY2024Jun 30, 2024$701.78M+17.1%
Q1 FY2024Mar 31, 2024$659.19M+18.2%
Q4 FY2023Dec 31, 2023$616.98M+1.2%
Q3 FY2023Sep 30, 2023$620.04M+13.7%
Q2 FY2023Jun 30, 2023$599.05M+7.1%
Q1 FY2023Mar 31, 2023$557.54M+12.0%
Q4 FY2022Dec 31, 2022$609.76M+13.6%
Q3 FY2022Sep 30, 2022$545.56M+3.2%
Q2 FY2022Jun 30, 2022$559.36M+4.5%
Q1 FY2022Mar 31, 2022$497.63M+0.9%
Q4 FY2021Dec 31, 2021$536.90M+5.3%
Q3 FY2021Sep 30, 2021$528.59M+1.8%
Q2 FY2021Jun 30, 2021$535.08M+15.2%
Q1 FY2021Mar 31, 2021$493.11M-1.1%
Q4 FY2020Dec 31, 2020$510.03M+28.4%
Q3 FY2020Sep 30, 2020$519.29M+37.3%
Q2 FY2020Jun 30, 2020$464.66M+14.8%
Q1 FY2020Mar 31, 2020$498.53M+11.7%
Q4 FY2019Dec 31, 2019$397.33M-20.1%
Q3 FY2019Sep 30, 2019$378.28M-20.6%
Q2 FY2019Jun 30, 2019$404.64M-2.2%
Q1 FY2019Mar 31, 2019$446.12M+62.1%
Q4 FY2018Dec 31, 2018$497.53M+69.6%
Q3 FY2018Sep 30, 2018$476.49M+87.1%
Q2 FY2018Jun 30, 2018$413.79M+59.2%
Q1 FY2018Mar 31, 2018$275.19M+21.9%
Q4 FY2017Dec 31, 2017$293.37M–
Q3 FY2017Sep 30, 2017$254.73M–
Q2 FY2017Jun 30, 2017$259.87M–
Q1 FY2017Mar 31, 2017$225.68M–

More Amneal Pharmaceuticals figures

See a number that looks wrong?